TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18569235

Group type: EXPERIMENTAL
Intervention: Patients citing drawbacks about asthma medications
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients citing benefits about asthma medications
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with asthma (overall population)
Number of subjects: 52
Study: 18572984

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 10
Study: 18580170

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia (66% for at least 2 hours)
Number of subjects: 140
Study: 18582195

Group type: EXPERIMENTAL
Intervention: MVA85A vaccination
Number of subjects: 24
Study: 18582371

Group type: EXPERIMENTAL
Intervention: The Treatment Perspective (16 week supervised training intervention including motivational counselling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: The Preventive Perspective (only motivational counselling)
Number of subjects: 0
Study: 18583924

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18584946

Group type: COMPARATOR
Intervention: Antimuscarinics (tolterodine ER 4 mg once daily)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Antimuscarinics (tolterodine ER 4 mg once daily) + local oestrogens (oestriol cream application once daily)
Number of subjects: 229
Study: 18589337

Group type: EXPERIMENTAL
Intervention: Site-independent telemedicine system used by telemedicine-naive examiners
Number of subjects: 25
Study: 18591547

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Number of subjects: 34
Study: 18591942

Group type: EXPERIMENTAL
Intervention: Exogenous 1,25-dihydroxyvitamin D administration
Number of subjects: 0
Study: 18592321

Group type: EXPERIMENTAL
Intervention: Hospitalists
Number of subjects: 372
Study: 18593770

Group type: EXPERIMENTAL
Intervention: Octreotide-long-acting release (LAR) therapy at a dose of 20 mg every 28 days for 3 months
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Octreotide-long-acting release (LAR) therapy
Number of subjects: 67
Study: 18596230

Group type: EXPERIMENTAL
Intervention: sCD22 levels in patients with HCL
Number of subjects: 93
Study: 18596272

Group type: EXPERIMENTAL
Intervention: Motesanib diphosphate (125 mg, orally once daily)
Number of subjects: 93
Study: 18598190

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine
Number of subjects: 1699

Group type: COMPARATOR
Intervention: Chloroquine (CQ) prophylaxis
Number of subjects: 1699
Study: 18598362

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (ABM MC) transplantation, 100 x 10^6 MC suspended in saline with 5% autologous serum
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (saline with 5% autologous serum)
Number of subjects: 300
Study: 18598891

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HT)
Number of subjects: 27736

Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (Control)
Number of subjects: 27736
Study: 18603291

Group type: EXPERIMENTAL
Intervention: Extracorporeal CPR
Number of subjects: 975

Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 975
Study: 18606624

Group type: EXPERIMENTAL
Intervention: Children with enterovirus 71 infection
Number of subjects: 86

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 86
Study: 18606979

Group type: EXPERIMENTAL
Intervention: Intensive therapy (original DCCT treatment group assignment)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Mean A1C values
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemic events
Number of subjects: 249

Group type: COMPARATOR
Intervention: Previous treatment group
Number of subjects: 249
Study: 18612103

Group type: EXPERIMENTAL
Intervention: Second autologous stem cell transplantation (ASCT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Reduced-intensity-conditioning allograft (allo-RIC)
Number of subjects: 110
Study: 18612102

Group type: EXPERIMENTAL
Intervention: dmCODOX-M (methotrexate, dose 3 g/m(2)) with or without IVAC
Number of subjects: 128
Study: 18615166

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18615172

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day) for 8 weeks
Number of subjects: 17
Study: 18615176

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 to 120 mg)
Number of subjects: 840
Study: 18617067

Group type: EXPERIMENTAL
Intervention: Continuation of beta-blockers (1,350 patients, 56.9%)
Number of subjects: 5791

Group type: COMPARATOR
Intervention: Withdrawal of beta-blockers (79 patients, 3.3%)
Number of subjects: 5791

Group type: COMPARATOR
Intervention: No beta-blocker therapy (303 patients, 12.8%)
Number of subjects: 5791

Group type: EXPERIMENTAL
Intervention: Newly started beta-blockers (632 patients, 26.6%)
Number of subjects: 5791
Study: 18619571

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab
Number of subjects: 79
Study: 18619874

Group type: EXPERIMENTAL
Intervention: Lacosamide 100mg/day, escalated by 100mg/day to a maximum of 400mg/day during the 20-week maintenance period and continued for up to 2.5 years in the extension period.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lacosamide treatment during the study.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lacosamide treatment at study termination.
Number of subjects: 69
Study: 18620563

Group type: EXPERIMENTAL
Intervention: Specialized addiction treatment plus treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 18621618

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus lapatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus both lapatinib and trastuzumab
Number of subjects: 0
Study: 18623174

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 18625666

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for > or = 4 h/night
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for < 4 h/night
Number of subjects: 32
Study: 18625762

Group type: EXPERIMENTAL
Intervention: High-dose lopinavir-ritonavir (LPV/r) 400/100 mg/m(2) p.o. q12h without NNRTI
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-dose lopinavir-ritonavir (LPV/r) 480/120 mg/m(2) p.o. q12h with NNRTI
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) 750 mg/m(2) p.o. q12h added when LPV IQ <15
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (LPV/r with or without SQV)
Number of subjects: 26
Study: 18626272

Group type: EXPERIMENTAL
Intervention: Aripiprazole (20, 25, or 30 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Aripiprazole (maximum dose for cohort for 14 days)
Number of subjects: 21
Study: 18627059

Group type: EXPERIMENTAL
Intervention: Genetic testing pursued by 83 individuals (8.3%)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Individuals who did not pursue genetic testing
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: United States residents who pursued genetic testing
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Canadian residents who pursued genetic testing
Number of subjects: 1001
Study: 18628574

Group type: EXPERIMENTAL
Intervention: Mixed-meal tolerance test (MMTT)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Glucagon stimulation test (GST)
Number of subjects: 266
Study: 18633105

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction immunosuppression followed by sirolimus and tacrolimus (no glucocorticoids)
Number of subjects: 7
Study: 18635429

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin and rituximab
Number of subjects: 20
Study: 18635722

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/day
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-225 mg/day
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 18639220

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant insertion combined with phacoemulsification and intraocular lens implantation
Number of subjects: 21
Study: 18640325

Group type: EXPERIMENTAL
Intervention: Postoperative neurocognitive dysfunction
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Mild atherosclerosis of the ascending aorta
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Duration of cardiopulmonary bypass (CPB)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Duration of aortic cross-clamping
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Length of postoperative hospitalization
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Apolipoprotein epsilon4 genotype
Number of subjects: 113
Study: 18641094

Group type: EXPERIMENTAL
Intervention: Continuous oxygen use
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Nonhypoxemic individuals not using oxygen
Number of subjects: 1215
Study: 18641097

Group type: EXPERIMENTAL
Intervention: Obese subjects (BMI > or = 30 kg/m(2))
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonobese subjects (BMI < 25 kg/m(2))
Number of subjects: 88
Study: 18641112

Group type: EXPERIMENTAL
Intervention: Pulmonary source of sepsis
Number of subjects: 288

Group type: COMPARATOR
Intervention: Nonpulmonary source of sepsis
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Pulmonary vs nonpulmonary source of sepsis
Number of subjects: 288
Study: 18643743

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and tigecycline catheter-lock solution for 14 days plus systemic antibiotic therapy
Number of subjects: 18
Study: 18644065

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 72
Study: 18647805

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in women with PCOS
Number of subjects: 52

Group type: COMPARATOR
Intervention: No OSA (control group)
Number of subjects: 52
Study: 18650451

Group type: EXPERIMENTAL
Intervention: pegylated IFN-alpha-2a
Number of subjects: 40
Study: 18650621

Group type: EXPERIMENTAL
Intervention: Adjuvant interferon-based chemoradiation followed by gemcitabine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (interferon- and gemcitabine-based)
Number of subjects: 53
Study: 18651943

Group type: EXPERIMENTAL
Intervention: Self-management program for cancer-related fatigue (CRF)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 300
Study: 18652942

Group type: EXPERIMENTAL
Intervention: Heart failure patients hospitalized with HF
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Risk-prediction algorithm for in-hospital mortality
Number of subjects: 48612
Study: 18652943

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 1000
Study: 18656877

Group type: EXPERIMENTAL
Intervention: Obese juveniles
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal weight controls
Number of subjects: 71
Study: 18657709

Group type: COMPARATOR
Intervention: Single-dose nevirapine (200 mg to women in labour and 2 mg/kg to newborns after birth)
Number of subjects: 2024

Group type: EXPERIMENTAL
Intervention: Extended-dose nevirapine (200 mg to women in labour and 2 mg/kg to newborns after birth plus 5 mg daily from days 8-42 for the infant)
Number of subjects: 2024
Study: 18657796

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (GDx-VCC)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (Stratus OCT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Confocal scanning laser ophthalmoscopy (HRT II)
Number of subjects: 109
Study: 18662932

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week for up to 20 weeks
Number of subjects: 1250
Study: 18663426

Group type: EXPERIMENTAL
Intervention: Benfotiamine plus alpha-lipoic acid
Number of subjects: 9
Study: 18663532

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted gastrectomy (LAG)
Number of subjects: 1485
Study: 18668591

Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1 Trap) 300 mg loading dose, followed by maintenance doses of 100 mg/week, with possible escalation to 160 mg/week and 320 mg/week.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1 Trap) 100 mg/week and higher doses (160 mg and 320 mg).
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1 Trap) at higher doses (160 mg and 320 mg).
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1 Trap).
Number of subjects: 5
Study: 18668653

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg by mouth every 8 hours for 6 weeks (initial 2-week titration).
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pentoxifylline treatment.
Number of subjects: 9
Study: 18669874

Group type: EXPERIMENTAL
Intervention: Thalidomide (THAL, 200 mg/d) with monthly pamidronate
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Partial response (PR) status
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low beta-2-microglobulin levels less than 2 mg/L
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Overall survival and event-free survival estimates
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Postsalvage therapy
Number of subjects: 76
Study: 18669875

Group type: EXPERIMENTAL
Intervention: MRD negative patients at day 100 after ASCT
Number of subjects: 295

Group type: COMPARATOR
Intervention: MRD positive patients at day 100 after ASCT
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: MRD(-) immunofixation-negative (IFx(-)) patients
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: MRD(-) immunofixation-positive (IFx(+)) patients
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: MRD status by MFC at day 100 after ASCT
Number of subjects: 295
Study: 18671877

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (10 g of gel containing 100 mg of testosterone)
Number of subjects: 10
Study: 18673542

Group type: EXPERIMENTAL
Intervention: Non-invasive cardiac imaging algorithm followed by evidence-based treatment (including CT calcium scoring, CT angiography, and DSMR testing)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: CT calcium scoring (control group)
Number of subjects: 1200
Study: 18675557

Group type: EXPERIMENTAL
Intervention: Prosthetic femoro-popliteal bypass
Number of subjects: 100
Study: 18681756

Group type: EXPERIMENTAL
Intervention: Citalopram, starting at 20 mg/day, increased to 40 mg/day by weeks 2-4, and to 60 mg/day by weeks 4-6.
Number of subjects: 2851

Group type: EXPERIMENTAL
Intervention: Citalopram treatment.
Number of subjects: 2851
Study: 18681768

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 18682513

Group type: EXPERIMENTAL
Intervention: Cabergoline (1.3 +/- 1.3 mg/wk, treatment duration 12-60 months in 32%, >60 months in 68%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cabergoline (cumulative dose above median)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cabergoline (cumulative dose below median)
Number of subjects: 50

Group type: COMPARATOR
Intervention: De novo patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study: 18682973

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
Number of subjects: 6
Study: 18684848

Group type: EXPERIMENTAL
Intervention: IBV(R) Valves (Spiration, Inc.) placed to occlude segmental and subsegmental bronchi in right and left upper lobes
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: IBV(R) Valves (Spiration, Inc.)
Number of subjects: 57
Study: 18687247

Group type: EXPERIMENTAL
Intervention: Delayed measurement of immunoreactive B-type natriuretic peptide (iBNP) levels
Number of subjects: 58465

Group type: EXPERIMENTAL
Intervention: Longer time to treatment
Number of subjects: 58465

Group type: EXPERIMENTAL
Intervention: Rales on initial examination
Number of subjects: 58465

Group type: EXPERIMENTAL
Intervention: Longer average time to iBNP draw
Number of subjects: 58465

Group type: EXPERIMENTAL
Intervention: Treatment delay
Number of subjects: 58465
Study: 18687248

Group type: EXPERIMENTAL
Intervention: PREPARE programming
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control cohort (EMPIRIC and MIRACLE ICD trials)
Number of subjects: 700
Study: 18687721

Group type: EXPERIMENTAL
Intervention: Migraine with aura
Number of subjects: 27519

Group type: EXPERIMENTAL
Intervention: Migraine with aura in lowest Framingham risk score group
Number of subjects: 27519

Group type: EXPERIMENTAL
Intervention: Migraine with aura in highest Framingham risk score group
Number of subjects: 27519

Group type: COMPARATOR
Intervention: Women without migraine
Number of subjects: 27519
Study: 18687759

Group type: EXPERIMENTAL
Intervention: Single SBP measurements
Number of subjects: 5140

Group type: EXPERIMENTAL
Intervention: Two SBP measurements at each site
Number of subjects: 5140

Group type: EXPERIMENTAL
Intervention: Detection of low ABI
Number of subjects: 5140

Group type: EXPERIMENTAL
Intervention: Average leg ABI
Number of subjects: 5140
Study: 18693069

Group type: EXPERIMENTAL
Intervention: Intrabone cord-blood transplantation
Number of subjects: 32
Study: 18694333

Group type: EXPERIMENTAL
Intervention: Fixed-dose pyronaridine-artesunate combination (6:2, 9:3, 12:4 mg/kg tablet coformulations and 9:3 mg/kg granule coformulation) administered once daily for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fixed-dose pyronaridine-artesunate combination
Number of subjects: 60
Study: 18694338

Group type: EXPERIMENTAL
Intervention: Single intramuscular dose of 90 microg of inactivated subvirion A/Vietnam/1203/2004 vaccine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Two 90-microg doses in H5-naive subjects
Number of subjects: 37
Study: 18697817

Group type: EXPERIMENTAL
Intervention: Sleep apnea (apnea-hypopnea index >or=5)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index 5 to 15
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index >or=15
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting or percutaneous coronary intervention
Number of subjects: 392

Group type: COMPARATOR
Intervention: No sleep apnea
Number of subjects: 392
Study: 18698002

Group type: EXPERIMENTAL
Intervention: Allogeneic donor peripheral blood cells infusion after fludarabine and 200 cGy total body irradiation, with posttransplantation cyclosporine and mycophenolate mofetil.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uninterrupted administration of highly active antiretroviral therapy (HAART).
Number of subjects: 0
Study: 18698342

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine
Number of subjects: 21
Study: 18703791

Group type: EXPERIMENTAL
Intervention: Inter-alpha-trypsin inhibitor (IaI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inter-alpha-trypsin inhibitor (IaI) deficiency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum IaI and HA levels in patients with IPF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High serum IaI and HA levels
Number of subjects: 0
Study: 18707849

Group type: EXPERIMENTAL
Intervention: Clarithromycin (1g within 1h of infusion for three consecutive days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 200
Study: 18708295

Group type: EXPERIMENTAL
Intervention: MRL (MR lymphoangiography)
Number of subjects: 375

Group type: COMPARATOR
Intervention: MDCT (multidetector CT)
Number of subjects: 375
Study: 18711462

Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV) implantation in UG patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ahmed glaucoma valve (AGV) implantation in OAG patients
Number of subjects: 68
Study: 18713945

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m2 per week)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Thalidomide and rituximab
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 25
Study: 18719057

Group type: EXPERIMENTAL
Intervention: Chronic mountain sickness patients (CMS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy men living at high altitude (HA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy men living at sea level (SL)
Number of subjects: 55
Study: 18722008

Group type: EXPERIMENTAL
Intervention: PTC124 at 16 mg/kg per day for 14 days (first cycle)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PTC124 at 40 mg/kg per day for 14 days (second cycle)
Number of subjects: 44
Study: 18723429

Group type: EXPERIMENTAL
Intervention: Unrelated donor umbilical cord blood transplantation
Number of subjects: 191
Study: 18725917

Group type: EXPERIMENTAL
Intervention: Lymphocyte depletion
Number of subjects: 0
Study: 18726086

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18726828

Group type: EXPERIMENTAL
Intervention: Leptin replacement treatment with recombinant methionyl human leptin for 24 months
Number of subjects: 1
Study: 18728159

Group type: EXPERIMENTAL
Intervention: Outpatient 1-yr intervention program based on exercise, behavior, and nutrition therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Obese children with NAFLD
Number of subjects: 36

Group type: COMPARATOR
Intervention: Obese children without NAFLD
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Changes of fetuin-A
Number of subjects: 36
Study: 18729192

Group type: EXPERIMENTAL
Intervention: PX-478 (20 mumol/L)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: PX-478 (50 mumol/L)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: PX-478
Number of subjects: 2
Study: 18729283

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 0
Study: 18753661

Group type: EXPERIMENTAL
Intervention: 4-mm needle for intramuscular injections
Number of subjects: 0